Allergan announces positive pivotal trial results for Oculeve Intranasal Tear Neurostimulator
DublinâAllergan announced that two pivotal trials of the Oculeve Intranasal Tear Neurostimulator, OCUN-009 and OCUN-010, each met their primary and secondary efficacy endpoints. With these new results, a premarket submission for the device is on-track to be submitted to the Food and Drug Administration (FDA) in the second half of 2016.
This handheld stimulator and daily disposable tips increases tear production upon stimulation in patients with dry eye disease due to decreased tear production. Several Oculeve Intranasal Tear Neurostimulator clinical studies with more than 200 adult patients show positive safety and efficacy of the device.
The OCUN-009 study is a prospective, randomized, controlled, double-masked, multicenter, cross-over trial in which participants used an active device and two control applications. The primary effectiveness endpoint of increased tear production over basal during intranasal application as measured by Schirmer score compared to both controls was met.
Recent: 3 steps to staff empowerment
The OCUN-010 study design is a prospective, single-arm, multicenter, open-label clinical trial in which participants used the Oculeve Intranasal Tear Neurostimulator to stimulate tear production for 180 days. The primary effectiveness endpoint of increased tear production as measured by Schirmer score during application of the device compared with basal Schirmer score at Day 180 was met. Secondary endpoints of increased tear production as measured by Schirmer score during application of the device compared with basal Schirmer score at Days 0, 7, 30, and 90 were also met.
All device-related adverse events were mild in nature. There were no device-related serious adverse events, and no patients discontinued treatment due to adverse events.